Should HTA look beyond the healthcare system?

When healthcare systems assess the value of a new medicine, should they only count the impact on the patient's health and the healthcare budget?   The case for a broader, societal perspective in health technology assessment has been building for years, but so have the arguments against it.   Grace Hampson is joined by Chris Skedgel, a Director at OHE, to dig into one of health economics' most contested methodological debates: what are health systems trying to achieve through health technology assessments (HTA)? And whose perspective should they adopt in doing so?  A Dose of Economics is Grace and the Office of Health Economics (OHE) team thinking out loud — debating the questions that matter most in healthcare policy, resource allocation, and health system decision-making, with the experts doing the work at the highest level. New episodes drop every Tuesday. For more on this topic, read OHE’s insight Valuing patient and carer time in HTA: equity and opportunity costIf there’s a topic you’d like us to cover, feel free to ⁠share your ideas⁠.